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H7N9 T-cell epitopes that mimic human
sequences are less immunogenic and may induce
Treg-mediated tolerance
Rui Liu1, Leonard Moise1,2, Ryan Tassone1, Andres H Gutierrez1, Frances E Terry2, Kotou Sangare3, Matthew T Ardito2,
William D Martin2, and Anne S De Groot1,2,*
1Institute for Immunology and Informatics; University of Rhode Island; Providence, RI USA; 2EpiVax Inc.; Providence, RI USA; 3Laboratory of Applied Molecular Biology (LBMA);
University of Bamako; Bamako, Mali
Keywords: cross-conservation, H7N9 influenza, immune evasion, immunoinformatics, JanusMatrix, regulatory T cells (Tregs),
tolerance, vaccine
Abbreviations: IAV, influenza A virus; TCR, T cell receptor; HI, hemagglutination inhibiting; A(H1N1)pdm09, pandemic H1N1;
H7N9, H7N9 avian influenza; HA, hemagglutinin; NA, neuraminidase; EBV, Epstein Barr Virus; HSV, herpes simplex virus; HIV,
human immunodeficiency virus; HCV, hepatitis C virus; HLA, human leukocyte antigen; Tregs, T regulatory cells; PBMC,
peripheral blood mononuclear cells; ICS, immunogenic consensus sequences; TRF, time resolved fluorescence; DPBS, Dulbecco’s
phosphate-buffered saline; ELISpot, enzyme-linked immunospot; SI, stimulation index; LAIV, live attenuated influenza vaccine
Avian-origin H7N9 inﬂuenza is a novel inﬂuenza A virus (IAV) that emerged in humans in China in 2013. Using
immunoinformatics tools, we identiﬁed several H7N9 T cell epitopes with T cell receptor (TCR)-facing residues identical
to those of multiple epitopes from human proteins. We hypothesized that host tolerance to these peptides may impair
T helper response and contribute to the low titer, weak hemagglutination inhibiting (HI) antibody responses and
diminished seroconversion rates that have been observed in human H7N9 infections and vaccine trials. We found that
the magnitude of human T effector responses to individual H7N9 peptides was inversely correlated with the peptide’s
resemblance to self. Furthermore, a promiscuous T cell epitope from the hemagglutinin (HA) protein suppressed
responses to other H7N9 peptides when co-administered in vitro. Along with other highly ‘human-like’ peptides from
H7N9, this peptide was also shown to expand FoxP3C regulatory T cells (Tregs). Thus, H7N9 may be camouﬂaged from
effective human immune response by T cell epitope sequences that avert or regulate effector T cell responses through
host tolerance.
Introduction
The discordant immunogenicity of vaccines developed for 2
distinct emerging influenza A viruses (IAV), 2009 pandemic
H1N1 (A(H1N1)pdm09) and H7N9 avian influenza (H7N9),
provides an opportunity to evaluate the role of T cells in the
development of effective humoral immune response. For exam-
ple, although A(H1N1)pdm09 was highly transmissible1,2 and
spread to more than 200 countries within 12 months of emer-
gence due to the lack of pre-existing antibodies,3,4 morbidity and
mortality due to the A(H1N1)pdm09 influenza were lower than
expected, presumably due to pre-existing T cell responses among
individuals exposed to or vaccinated with seasonal A(H1N1)
strains.5 H7N9’s emergence in China in 20136 was associated
with much higher lethality. Due to concerns about its lethality
and pandemic potential, H7N9 vaccines were prioritized for
production.7
In stark contrast with A(H1N1)pdm09, unadjuvanted H7N9
vaccines were poorly antigenic and vaccination with unadju-
vanted H7N9 hemagglutinin (HA) resulted in hemagglutination
inhibition (HI) seroconversion rates of only 6% and 15.6% in
Phase I clinical trials8,9 (as compared to 89% for similar unadju-
vanted A(H1N1)pdm09 subunit vaccines10). Even when 2 doses
of H7N9 vaccine were administered with adjuvant, only 59% of
subjects seroconverted in a recent Phase II clinical trial.11 The
development of neutralizing antibodies to H7N9 is also delayed
in H7N9-infected humans, when compared to the typical
immune response to other IAV infections, and IgG avidity to
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H7N9 HA is significantly lower.12 In clinical trials of other H7
subtypes, an attenuated H7N1 vaccine elicited low HI titers,13
and an inactivated subunit H7N7 vaccine was poorly immuno-
genic.14 H7 HA appears to be uniquely non-antigenic: human
antibody response to a related H7 HA in the H7N7 outbreak in
2003 in the Netherlands was also diminished in HI titer.15 Taken
together, these studies suggest that adaptive immune responses to
H7N9 infection may be diminished and delayed, even in the
context of natural infection.
Limited T helper response could explain the attenuation of
humoral immunity to H7N9. CD4C T cells provide help to B
cells, supporting isotype conversion and affinity maturation16,17;
thus, these clinical results suggest that T cell help was limited or
abrogated. We previously reported that there are fewer CD4C T
helper epitopes in the H7N9 sequences than in other IAV.18
Similar patterns of epitope deletion have been observed in
chronic (‘hit-and-stay’) viruses that have adapted to the human
host, such as Epstein-Barr virus (EBV) and herpes simplex virus
(HSV), but not in acute (‘hit-and-run’) viruses.19 Immune escape
mediated by epitope deletion is a well-established mechanism of
viral pathogenesis for human immunodeficiency virus (HIV) and
hepatitis C virus (HCV),20,21 but this escape mechanism has not
been previously described for influenza.
Another means by which H7N9 may minimize host response
is to adopt ‘immune camouflage’, a new mechanism of immune
escape identified by our group. T cell epitopes derived from
pathogens that have high T cell receptor (TCR) ‘cross-con-
servation’ with human sequences can be identified using Janus-
Matrix, an algorithm that compares TCR-facing patterns of
CD4C T cell epitopes.22 Commensal viruses contain a signifi-
cantly higher number of these JanusMatrix-defined ‘human-like’
T cell epitopes than viruses that do not establish chronic infec-
tions in humans.19
For example, we have identified an epitope in HCV that is
highly cross-conserved with self and significantly expands T regu-
latory cells (Tregs) in vitro. T cells that respond to this peptide
exhibit markers that are characteristic of Tregs and actively sup-
press bystander effector T cell responses in vitro.23 The striking
difference observed between commensal viruses, which appear to
have many such epitopes, and acute-disease, pathogenic viruses,
suggests that immune camouflage may be an important method
by which certain human pathogens escape adaptive immune
response.24
When evaluating the potential immunogenicity of H7N9
using our computational tools, we identified several H7N9
CD4C T cell epitopes that are more cross-conserved with human
sequences than were similar epitopes found in other influenza
strains. Notably, an H7 HA sequence that corresponds in
sequence location to an immunodominant epitope of A(H3N2)
and A(H1N1) bears mutations at TCR-facing positions that
increase its resemblance to self antigens in the context of human
leukocyte antigen (HLA)-DR presentation. We considered the
possibility that these human-like H7N9 epitopes might reduce
H7N9 vaccine efficacy and contribute to lower titer, lower affin-
ity antibody development.25 We therefore performed in vitro T
cell assays using peripheral blood mononuclear cells (PBMC)
from na€ıve human donors, examining the phenotype and func-
tion of cells responding to H7N9 class II-restricted T cell epito-
pes that are cross-conserved with the human genome, and
compared responses to these peptides with responses to corre-
sponding peptides derived from human proteins and to less
cross-conserved peptides in H7N9. As described here, we con-
firm that highly cross-conserved epitopes contained in H7N9
protein sequences exhibited low immunogenicity and stimulated
functional Tregs, a finding that has significant implications for
H7N9 vaccines and viral immunopathogenesis.
Results
Genome analysis and epitope prediction
In previously published work, we analyzed 4 human H7N9
influenza sequences (A/Hangzhou/1/2013, A/Anhui/1/2013, A/
Shanghai/1/2013, and A/Shanghai/2/2013) from GISAID
(http://platform.gisaid.org/) for HLA class II-restricted epitopes,
and constructed immunogenic consensus sequences (ICS) to
enable broad HLA and strain coverage.18 For the present study,
we selected 15 representative ICS from the original publication
with varying degrees of cross-conservation with self. An addi-
tional 4 published influenza A epitopes from A(H1N1), A
(H3N2), and A(H5N1) and 5 peptides from human proteins
were selected to serve as positive controls and human ‘analogs’ of
the H7N9 peptides, respectively. The human analog peptides
were among those identified by JanusMatrix as likely targets of
mimicry by selected H7N9 peptides.
A quantitative measure of human genome cross-conservation
called ‘JanusMatrix Delta’ was calculated for all peptides; scoring
is described in detail in the Methods. A higher JanusMatrix Delta
indicates a greater number of TCR matches with autologous
(human) peptides, which themselves share HLA restrictions with
the query peptide. JanusMatrix Delta values for the peptides used
in this study ranged from 0 to 37.89. A complete list of peptides,
along with their sequence similarity to corresponding peptides in
circulating IAV strains and cross-conservation with the human
genome, is provided in Table 1.
So as to visualize the peptide relationships identified by Janus-
Matrix, we used Cytoscape to provide a qualitative analysis of the
predicted cross-reactivity between each peptide and the human
genome.26 Figure 1 shows Cytoscape networks for each of the
peptides included in this study.
Class II HLA binding assay
HLA class II binding affinity assays were performed to validate
the computational predictions. All 24 peptides were evaluated for
binding affinity in competition assays for 5 common HLA
DRB1 alleles: HLA DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, and DRB1*0801 (Fig. S1). Of all the peptide-
HLA binding interactions assayed, 50% displayed strong binding
affinity (estimated IC50<1mM), 13% showed moderate binding
(1mM < estimated IC50<10mM), 11% showed weak binding
affinity (10mM < estimated IC50<100mM) and 11% exhibited
no significant affinity (estimated IC50>100mM) to the target
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allele. In 18 cases, the data were not sufficient to establish binding
affinity.
The concordance of computational predictions and binding assay
results was evaluated by classifying peptide-HLA binding pairs as
either true positive (TP), false positive (FP), true negative (TN), or
false negative (FN). For a given HLA allele, an EpiMatrix Z-score
1.64 indicates that the peptide is in the top 5% of predicted binders
and is considered a ‘hit’. The overall predictive success rate was 85%,
excluding indeterminate measurements. The correlation between
prediction and binding was 82% for DRB*0101, 75% for
DRB1*0301, 95% for DRB1*0401, 73% for DRB1*0701, and
100% for DRB1*0801 (Fig. 2). These correlations fall in the range
of previously published results for IAV peptides predicted using
EpiMatrix.27,28
HLA-DR blocking assay
To identify whether the peptides were presented by HLA-DR,
we examined the effect of an anti-HLA-DR antibody on the
epitope-specific T cell responses by IFNg enzyme-linked
immunospot (ELISpot) in 3 healthy donors. For ten of the pepti-
des (IAV-1, H7N9-2, -4, -7, -9, -12, -13, -14A, 5-HUMAN-A,
and -B), peptide-specific spot formation was 100% inhibited by
blocking HLA-DR, indicating that these peptides are restricted
by HLA-DR (Table 2).
Seven of the predicted peptides (IAV-2, -3, -4, H7N9-1, -3,
-8, and -10) induced T cell responses that were only partially
inhibited by blocking HLA-DR. This may be due to presentation
by another HLA molecule such as HLA-DP, HLA-DQ, or class I
HLA in addition to (or instead of) HLA-DR. Indeed, several of
the peptides in this category contained class I HLA binding
motifs that were identified by EpiMatrix (data not shown). In
the case of peptide H7N9-11, response was absent except when
HLA-DR was blocked, suggesting that other HLA alleles may
present this peptide.
T cell reactivity of individual peptides
PBMC from 18 individual healthy donors were stimulated in
culture with individual peptides over 8 days, and human IFNg
Figure 1. Three categories of peptides analyzed in JanusMatrix for human sequence cross-conservation. Cross-conservation with the human genome,
visualized in Cytoscape networks, is shown. Each peptide is represented by a green diamond. HLA-binding 9-mer frames contained within the source
peptide are depicted as gray squares. For each 9-mer frame, human 9-mers with similar HLA binding afﬁnities and identical TCR-facing residues are
shown as dark blue triangles, and the human proteins from which they are derived are shown as light blue circles. Accordingly, peptides with limited
cross-conservation to the human genome have sparse networks surrounding the central node, and peptides with high cross-conservation to the human
genome have more complex, interconnected networks with many branches.
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production was measured in response to restimulation with indi-
vidual peptides in ELISpot assays (Fig. 3A). ELISpot assays were
performed following a cell expansion phase because ex vivo
responses to the peptides did not rise significantly above back-
ground at 24–48 hours, suggesting that epitope-specific T cell fre-
quencies were too low to detect without expanding precursor
populations (data not shown). The data were analyzed by calculat-
ing the stimulation index (SI) of each response. Although the vari-
ability among donor responses was high, when the average
ELISpot SI was plotted against the JanusMatrix Delta value for
Figure 2. Comparison of immunoinformatic predictions and HLA bind-
ing in vitro. The HLA class II binding result for each peptide was com-
pared to its EpiMatrix Z-score for the corresponding HLA allele. True
positive (black) reﬂected correctly predicted HLA-binding peptide
results. False positive (gray) reﬂected incorrectly predicted HLA-binding
peptide results. False negative (white) reﬂected incorrectly predicted
non-binding peptide results. No true negatives, which reﬂected correctly
predicted non-binding peptide results, were found. The correspondence
between predicted binding and observed binding was high, and consis-
tent with previous observations.
Table 2. Inhibition of peptide-speciﬁc responses by HLA-DR blocking
antibody
Peptide Name % Inhibition by HLA-DR blocking Ab
IAV-1 100%
IAV-2 73%
IAV-3 78%
IAV-4 96%
H7N9-1 46%
H7N9-2 100%
H7N9-3 97%
H7N9-4 100%
H7N9-5 N/A
H7N9-6 N/A
H7N9-7 100%
H7N9-8 89%
H7N9-9 100%
H7N9-10 68%
H7N9-11 increased response
H7N9-12 100%
H7N9-13 100%
H7N9-14A 100%
H7N9-14B N/A
5_HUMAN-A 100%
5-HUMAN-B 100%
12-HUMAN N/A
14A-HUMAN N/A
PBMC were incubated with H7N9 peptides and controls in the presence or
absence of an anti-HLA-DR blocking antibody as described in Methods.
Most peptide-speciﬁc responses were inhibited by the addition of the anti-
body, suggesting the peptides were indeed presented by HLA-DR mole-
cules. However, as the inhibition was not always complete, and in one case
(H7N9-11) the response increased in the presence of the blocking antibody,
the possibility of presentation by other class II alleles (DP, DQ) and/or class I
HLA cannot be ruled out. N/A: response in absence of blocking Ab was
below assay background.
Figure 3. Human IFNg responses to individual H7N9 peptides and con-
trols. (A) The chart depicts the individual (circles) and average (bars) SI
across donors (n D 18). The H7N9 peptides are arranged on the chart
according to the degree of predicted cross-conservation with peptides
from the human genome, as measured by JanusMatrix Delta. (B) The
average response to each peptide across 18 healthy donors, as measured
by SI, was signiﬁcantly negatively correlated with the JanusMatrix Delta,
which is a measure of cross-conservation with self. More speciﬁcally,
peptides presenting the same amino acids to T cells as human protein
sequences were signiﬁcantly less immunogenic in vitro.
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each peptide, a significant negative correlation (p < 0.05) was
observed, as shown in Figure 3B. A regression model relating
averaged SI to JanusMatrix Delta was significant (F significance
0.02) but underpowered (Power 0.65). By considering all 432
data points generated from this 24-peptide screen of 18 subjects,
JanusMatrix Delta was identified as a significant and well-powered
predictor of variation in SI (F significance 0.004, Power 0.85).
T cell reactivity of pooled peptides
So as to relate the observation described above more specifi-
cally to H7N9 infection and/or vaccination, we performed the
same experiment with 2 peptide pools (Fig. 4). The first pool
was comprised of H7N9 ICS peptides with JanusMatrix Delta
values between 10 and 20 (H7N9-4 to -12), and the second pool
contained peptides with JanusMatrix Delta values higher than 20
(H7N9-13 to -14B). Because there were more peptides in the
first pool than the second, the pool concentrations were equalized
to achieve the same total per unit of volume. In 4 of the 5 tested
individuals, the SI values of the second pool, consisting of the
most human-like H7N9 peptides, were lower than the first pool.
The other individual responded with the same SI values to the 2
peptide pools. In summary, the mean SI of the second pool was
significantly lower than that of the first pool (p < 0.05).
These results reflect the responses of 5 donors. As there may
have been significant variation between subjects due to HLA dif-
ferences, additional studies were performed. For example, we
also pooled peptides in groups according to their predicted
immunological properties, their similarity to circulating IAV,
cross-conservation with human sequences, or status as self anti-
gens, and the results were consistent with those observed for the
individual peptides in the pools (Fig. S3).
Treg phenotyping
Peptides were also tested individually for their ability to
expand Tregs in healthy donor PBMC. All three peptides with
JanusMatrix Delta values greater than 20 induced the expansion
of significantly higher proportions of CD3CCD4CFoxP3CT cells
in vitro (n D 3) (Fig. 5, p < 0.05) than culture medium. We
observed similar trends in the frequency of CD25CFoxP3C and
CD39CFoxP3C Tregs in the same assays (Fig. S5), although
only the increase in CD39CFoxP3Cfrequency was statistically
significant. Pooled influenza A epitopes that are similar to circu-
lating IAV did not induce a similar expansion of CD25CFoxP3C
and CD39CFoxP3C T cells in vitro (n D 9) (Fig. S4).
Bystander suppression
We performed bystander suppression experiments to deter-
mine whether a peptide with known HLA promiscuity and a
human TCR signature could exert a regulatory effect on adjacent
inflammatory responses, as may occur in natural infection or vac-
cination. Normal subject PBMC were stimulated with a pool of
H7N9 ICS peptides (including all except H7N9-1, -2, -9, and
-13) in the presence or absence of peptide H7N9-13, the H7
homolog of the seasonal influenza HA immunodominant epi-
tope. This peptide had a JanusMatrix Delta value of 21.85. To
ensure that the pool was not diluted by the addition of H7N9-
13, the concentrations were adjusted so that both cultures had
the same absolute concentration of the pooled peptides, with the
addition of H7N9-13 being the only variable. Coincubation
with H7N9-13 significantly suppressed T cell response to the
pooled peptides in 6 of the 7 tested individuals (Fig. 6A,
p < 0.01).
In contrast, coincubation with peptide H7N9-9, which is not
as cross-conserved with the human genome as H7N9-13, did not
suppress T cell responses to the pool of H7N9 epitopes in all 4
individuals tested (Fig. 6B), suggesting that the immunosuppres-
sive activity of H7N9-13 is peptide-specific.
To confirm this effect using peptides from other IAV strains,
the same experiment was performed using individual or pooled
peptides from the HA of circulating IAV strains (IAV-1 through
-4) or an H7N9 peptide from M1 with high similarity to the
sequence of circulating IAV strains (H7N9-3). Using PBMC
from 2 individual donors, peptide H7N9-13 significantly sup-
pressed T cell response to IAV-3 when co-cultured with H7N9-3
as compared to responses to IAV-3 in the absence of H7N9-3;
similar reductions in T cell responses were observed to peptide
IAV-1 in the first donor and IAV-2 in the second when H7N9-3
was present (Fig. 6C, all p < 0.05). Reduced responses to the
pool of IAV peptides (1–4) were also observed in the presence of
H7N9-13, -14A and -14B, which also had high JanusMatrix
Delta scores (>20), though these reductions were not statistically
significant (Fig. S6).
Discussion
Influenza vaccines can call upon memory T cells to generate
protective immunity and stimulate antibody response in the
Figure 4. Human IFNg responses to pooled H7N9 peptides. Human IFNg
responses to pools composed of H7N9 peptides with different levels of
human genome cross-conservation were measured in PBMC from
healthy donors (nD5). The SI upon re-stimulation with the same peptides
in ELISpot was signiﬁcantly lower (*p < 0.05) in the PBMC that received
the more human-like peptides. Lines connect data collected from the
same donor.
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absence of adjuvants; thus, usually only
one vaccination is required to generate
protective immunity to seasonal influ-
enza strains. Traditionally, vaccines
developed for new influenza subtypes
such as A(H1N1)pdm09 and H7N9
(for which cross-reactive humoral
immunity is presumed to be absent),
have been adjuvanted to improve
immunogenicity, and 2 immunizations
are recommended to generate new
memory T helper cells to the novel
virus. However, pre-existing heterotypic
T cell memory specific for epitopes con-
tained in the new flu strain may obviate
the need for adjuvants and effective
antibody titers may develop following a
single dose, as was observed for A
(H1N1)pdm09.29 Thus, the T cell epi-
tope content of vaccine immunogens
appears to be a critical contributor to
protective immunity. Adjuvanting
poorly antigenic vaccines can amplify
low-level T cell responses, augmenting
the contribution of the few epitopes
that are present to improve protective
antibody titers.
While T cell epitopes that recall pre-
existing immunity may help protect
against multiple viral subtypes as was
observed for A(H1N1)pdm09 influ-
enza,30 epitopes that resemble host
sequences may be detrimental to immu-
nity. Using the JanusMatrix tool, we
identified epitopes in H7N9 that are
cross-conserved with multiple predicted
HLA ligands from human proteins.
Based on our previous discovery of
human-like Treg epitopes in HCV,23
we hypothesized that similarly cross-
conserved epitopes in H7N9 might be
responsible for the attenuation of adaptive immunity to H7N9.
As exposed donor blood was not available, we evaluated the
responses of H7N9-na€ıve subject PBMC to H7N9 influenza T
cell epitope peptides. Even though the response of individual
peptide varied in different subjects (Fig. 3A), it was inversely cor-
related with their degree of cross-conservation with the human
genome on their TCR face (Fig. 3B). The high variability in
antigen-specific IFNg release that is observed in ELISpot assays
using whole PBMC cultures may be attributable to multiple fac-
tors including (i) efficiency of antigen presentation, (ii) binding
affinity of a peptide for an individual’s HLA type, (iii) availability
of T cells with TCRs that recognize the peptide-HLA complex,
and (iv) competition between T cells for domains on the antigen-
presenting cells. A further source of variability is that the peptides
tested comprise multiple 9-mers with potential to bind HLA. It is
the sum of IFNg responses to the individual 9-mers, each of
which is governed by the factors described above, that is mea-
sured in the ELISpot assay, which further compounds variability.
Despite the high potential for inconsistency, a clear inverse corre-
lation emerges with 65% power in an “averaged data” model and
85% power in an “all data” construct. Future studies that mea-
sure responses to individual 9-mers would help reduce variability
and strengthen the correlation.
Hypothesizing that attenuation of response could be due to
Tregs that recognize the H7 epitopes, we discovered that Tregs
expand in vitro in co-cultures with the human-like H7 epitopes
(Fig. 5). We also confirmed the functionality of these expanded
Tregs in bystander suppression assays (Fig. 6). While the exact ori-
gin of the Treg cells that respond to the human-like H7N9 epito-
pes remains to be defined (thymic-derived natural Tregs or
Figure 5. Treg cell expansion. Human-like peptides from H7N9 induced Treg expansion. (A) The gat-
ing strategy was based on live CD3Clymphocytes, then analyzed for CD4 vs FoxP3. (B) Representative
results for a single subject are shown in the dot plots, with the averages for 3 subjects shown in the
chart below. *p<0.05.
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induced peripheral Tregs), the implications for vaccine develop-
ment are clear. If, in the context of natural infection or unadju-
vanted vaccination using H7N9 HA, Treg responses are
induced by these epitopes, humoral immune responses may be
diminished and delayed, as has been reported in H7N9 infection.12
Although exploration of the impact of Treg epitopes and
Tregs on humoral immune responses in the context of infection
is relatively new,31 we have described the importance of Treg-
activating epitopes derived from IgG (now known as
‘Tregitopes’) in the context of anti-drug antibodies to protein
therapeutics.32-34 In a retrospective analysis of published viral
epitopes in a large epitope database, greater human cross-conser-
vation was associated with absent or Treg responses.19 Taken
together, these findings demonstrate that certain human patho-
gens may evolve to contain T cell epitopes in their proteomes
that resemble important human Treg epitopes, a phenomenon
we have called ‘immune camouflage’.24
The T cell epitope profile of H7N9 (few effector T cell epito-
pes and many cross-conserved epitopes) is much closer to these
‘hit-and-stay’ viruses than viruses that ‘hit-and-run’ as described
in our previous publication on host pathogens.19 Although
human-to-human transmission of H7N9 is rare, the virus has
been noted to have a ‘mammalian signature’.35,36 Cases of
human-to-human transmission case
have been reported.37 Perhaps human-
to-human transmission of H7N9 occurs
more frequently than suspected,38 as it
is harder to detect due to low titers of
antibody. The discovery of human-like
epitopes in the H7N9 proteome raises
an important question about the origin
and evolution of H7N9 and the dura-
tion of its circulation in human beings
or other mammals.
Building on our previous work, this
report provides additional in vitro evi-
dence that T cells responding to epito-
pes that are cross-conserved between
pathogens and their hosts may be
immunomodulatory; a discovery that
deserves further investigation in other
human pathogens.
The discovery of these T cell epito-
pes (and others like them) was possible
using a new tool, JanusMatrix. Janus-
Matrix is a homology analysis tool that
considers aspects of antigen recognition
that are not captured by raw sequence
alignment. At the level of the TCR-
HLA-II-peptide interaction, there is evi-
dence to support the designation of
amino acids in positions 2, 3, 5, 7, and
8 as ‘TCR-facing’39; these are used to
identify homologous epitopes in sets of
peptides predicted to be restricted by
the same HLA. The same authors also
describe a role for several positions in the class II HLA ligand
that lie outside of the central binding groove, notably at the N-
terminus. Currently, the JanusMatrix tool does not integrate the
contributions of these distal residues. Further studies are needed
to determine whether these residues would improve the discovery
of cross-conserved epitopes with the JanusMatrix tool.
For this study, we limited the JanusMatrix evaluation of
‘analogs’ to human-origin peptides that were cross-conserved
with selected H7N9 ICS peptides, and did not evaluate the influ-
ence of TCR cross-conservation with epitopes derived from other
human pathogens, or from human commensals. Others have
been pioneers in that regard, establishing evidence for immune
modulation (termed ‘heterologous immunity’) in a range of viral
infections; these studies have focused on class I HLA-restricted
epitopes.40,41 Epitopes that are cross-conserved with the human
microbiome have also been described, and may contribute to T
cell reactivity.42
Cross-reactivity with human pathogens or commensals may
explain in part why one of the H7N9 ICS peptides, H7N9-2,
was more immunogenic in vitro, in H7N9-unexposed donor
PBMC than H7N9-1, despite their lack of similarity to circulat-
ing strains of IAV (Fig. 3A). We applied JanusMatrix to retro-
spectively analyze these peptides, but instead of searching the
Figure 6. Suppressive activity of the H7 homolog of the seasonal inﬂuenza immunodominant HA epi-
tope. Peptide H7N9-13, the H7N9 variant of an immunodominant HA epitope, was associated with a
reduction in T cell response when co-administered with other peptides. Healthy donor ELISpot
responses to a pool of H7N9 peptides were signiﬁcantly decreased in the presence of H7N9-13 (n D 7)
(A), but not H7N9-9, a less human-like peptide (n D 4) (B). H7N9-13 was able to suppress responses to
other immunodominant HA peptides from circulating IAV strains (n D 2) (C). Lines connect data col-
lected from the same donor. *p < 0.05. **p < 0.01.
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human genome for matches, we searched databases of bacterial
and viral pathogens.43,44 JanusMatrix identified 168 HLA-bind-
ing sequences from the databases that present the same amino
acids to the TCR as peptide H7N9-2. By contrast, only 7 such
sequences were found corresponding to peptide H7N9-1, which
was less immunogenic in vitro. Pre-existing memory T cells,
expanded in the course of past infections, may have contributed
to the response observed to H7N9-2.
With so many possible avenues for cross-reactivity at the TCR
face of like-HLA-binding peptides, the calculation of a fully pre-
dictive metric for T cell epitope response remains an elusive goal.
Previously, we identified a ratio of human genome to human
microbiome cross-conservation that was associated with a regula-
tory, rather than effector, T cell response.22 Here, we used the
JanusMatrix Delta score, which was significantly inversely corre-
lated with the magnitude of effector T cell response (Fig. 3B).
Additional prospective studies and retrospective analyses need to
be performed to better define how JanusMatrix Delta or other
measures of ‘human-ness’ can be used to predict the phenotype
of T cells responding to specific epitopes.
Experiments performed on H7N9-infected cells would be
instructive for the elaboration of these important relationships,
but we did not have access to H7N9-exposed subjects in Provi-
dence, RI. Instead, we examined T cell responses in restimulation
assays using PBMC from unexposed donors. These in vitro stud-
ies of na€ıve donors are still relevant, since the responses observed
may be representative of responses that might be generated fol-
lowing vaccination or infection of H7N9-unexposed human
subjects.45
Finally, we limited our studies to a manageable number of
possible T cell epitopes from H7N9 and did not complete a com-
prehensive analysis of all H7N9 cross-conserved epitopes. None-
theless, these studies serve as a benchmark against which future
in vitro studies can be conducted for H7N9 and other influenza
strains. Future studies should also examine the impact of these
immunomodulatory H7N9 epitopes on CD8C T cell
responses.46,47 We are now evaluating whether removal or modi-
fication of the human-like epitopes that trigger Tregs will
improve vaccine efficacy in vivo.
In conclusion, H7N9 influenza T cell epitopes that have a
high degree of cross-conservation with the human host can
expand Tregs in vitro and reduce IFNg secretion in PBMC when
co-incubated with other H7N9 peptides, in contrast to epitopes
that are less cross-conserved with self. When this study is consid-
ered in the context of previous work by our group and other labo-
ratories,23,25 cross-conservation of T helper epitopes with epitope
sequences in the human proteome appears to be an important
modulator of immune response to viral pathogens.
Modulation of T and B cell responses by these human-like
epitopes probably reduces the titer and affinity of neutralizing
antibodies to H7N9 HA, in vaccination and infection. In addi-
tion to posing a barrier to the success of conventional approaches
currently being used to develop H7N9 vaccines, ‘immune cam-
ouflage’ can be added to the list of mechanisms by which human
pathogens may escape from or modulate human immune
defense.
Materials and Methods
Peptide similarity to circulating IAV and cross-conservation
with human genome
The similarity of H7N9 peptides to other IAV strains was
identified as previously published.18 Cross-conservation with the
human genome was evaluated using JanusMatrix.22 In this analy-
sis, we translated the UniProt reviewed human genome data-
base48 as the source of human sequences for comparison.
H7N9 ICS peptides were generated as previously described.18
Given a peptide containing multiple HLA-binding 9-mer frames,
JanusMatrix divides each such frame into T cell receptor-facing
residues (positions 2, 3, 5, 7, and 8) and HLA-binding residues
(positions 1, 4, 6, and 9).39 Subsequently, JanusMatrix searches
for potentially cross-conserved epitopes (100% TCR-facing iden-
tity and predicted to bind at least one of the same HLA super-
types) in the human genome database. Finally, a differential
(Delta) score is calculated by applying a user-defined deduction
to each EpiMatrix hit in the source peptide for each TCR-
matched 9-mer found in the human genome (set for the purpose
of the current study at 10% of the human 9-mer’s Z-score). After
deduction, the hits in the source peptide are summed and used to
calculate a JanusMatrix-adjusted Cluster Score. The difference
between a peptide’s original EpiMatrix Cluster Score and its
JanusMatrix-adjusted Cluster Score is called the JanusMatrix
Delta. A higher JanusMatrix Delta value implies that the original
potential for immunogenicity may be discounted by greater
cross-conservation with the human genome. The calculation is
illustrated below:
JanusMatrix Delta D EpiMatrix Cluster Score
¡ JanusMatrix-adjusted Cluster Score
Grouping peptides by predicted immunological properties
To compare immune responses to IAV epitopes in vitro using
human PBMC, IAV peptides that could elicit several types of
possible immune responses were selected in this study. The first
group consisted of peptides representing variants of the immuno-
dominant and highly conserved HA epitope, from IAV strains
other than H7: A(H1N1), A(H3N2) and A(H5N1).49-52
The second group of peptides was selected from a list of ICS
peptides derived from the H7N9 antigens (H7N9 ICS peptides)
identified in a previous publication.18 A subset of the 101 ICS
generated by the EpiAssembler algorithm were selected for this
study on the basis of promiscuous HLA binding potential, lack
of cysteines and hydrophobic domains known to result in diffi-
culties with peptide synthesis, and predicted TCR/HLA matches
with the human genome using the JanusMatrix algorithm
described above. The H7N9 ICS peptides are ordered by their
JanusMatrix Delta scores. In some of the assays described, this set
of peptides was further separated into pools according to their
degree of cross-conservation with the human genome.
For those H7N9 peptides with the most extensive human
cross-conservation, one or 2 peptides from human sequences
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with which the corresponding H7N9 peptide shared TCR-facing
residues were selected for synthesis. These human ‘analog’ pepti-
des were numbered by the H7N9 peptide with which they share
TCR-facing amino acids. For example, 12-HUMAN is the
human analog of peptide H7N9-12.
Peptide synthesis
Synthetic peptides were manufactured using 9-fluoronylme-
thoxycarbonyl (Fmoc) chemistry by 21st Century Biochemicals
(Marlboro, MA). Peptide purity was >80% as ascertained by
analytical reversed phase HPLC. Peptide mass was confirmed by
tandem mass spectrometry.
Class II HLA binding assays
Class II HLA binding assays were performed to screen pre-
dicted epitope sequences for binding to multiple HLA alleles as
previously described.53 Briefly, non-biotinylated test peptides
over 3 concentrations (1, 10, and 100 mM) were used to compete
for binding against a biotinylated standard peptide (25 nM) to
soluble class II molecules (Benaroya Institute, Seattle, WA). The
reaction was incubated at 37C for 24 hours to reach equilib-
rium. Class II HLA-peptide complexes were then captured on
96-well plates coated with pan anti-HLA-DR antibodies (L243,
anti-HLA-DRA, BioXCell). The microwell plates were then
washed to remove excess peptide and incubated with Europium-
labeled streptavidin (Perkin-Elmer) for one hour at room tem-
perature. Europium activation buffer (Perkin-Elmer) was added
to develop the plates for 15-20 minutes at room temperature
before the plates were read on a Time Resolved Fluorescence
(TRF) plate reader. Assays were performed in triplicate. Binding
assays were performed for all 24 peptides, for 5 alleles:
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, and
DRB1*0801, a selection of HLA class II alleles that provides a
broad representation of class II HLA allele binding pockets. 54
PBMC isolation
Leukocyte reduction filters were obtained from de-identified
healthy donors (Rhode Island Blood Center, RI) and buffy coats
were obtained from age-identified healthy donors (Research
Blood Components, MA). All studies using human blood were
performed in accordance with NIH regulations and with the
approval of the URI institutional review board.
All leukocyte reduction filters and buffy coats were obtained
and processed on the same day as the blood was drawn. Fresh
PBMC were isolated from leukocyte reduction filters or buffy
coats by Ficoll density gradient centrifugation as follows: leuko-
cyte reduction filters were back-flushed by Hank’s Balanced Salt
Solution (HBSS, Cellgro, Manassas, VA) with 2.5% sucrose and
5mM EDTA (pH D 7.2). Buffy coats were removed by a syringe
and diluted in Dulbecco’s Phosphate-Buffered Saline (DPBS,
Thermo Fisher Scientific, Waltham, MA). Blood from filters or
buffy coats was underlaid with Ficoll (Histopaque 1077, Sigma-
Aldrich, St. Louis, MO) before centrifugation to isolate mononu-
clear cells. PBMC were transferred to separate tubes and washed
twice in DPBS. PBMC were then resuspended in cell culture
medium: RPMI 1640 (Cellgro) with 10% human AB serum
(Valley Biomedical, Winchester, VA), 1% L-glutamine (Life
Technologies, Carlsbad, CA) and 0.1% Gentamycin (Cellgro).
PBMC culture
Freshly isolated PBMC were cultured with individual peptides
(10 mg/ml) or pools of peptides (10 mg/ml) over 8 days at 37C
under a 5% CO2 atmosphere to expand antigen-specific T cells.
Prior to placing the peptides in culture, they were dissolved in
DMSO and further diluted in culture medium. The maximum
concentration of DMSO per peptide per well was 0.2%. In wells
of a 48-well cell culture plate, 2 £ 106 cells in 150 ml of culture
medium were stimulated with 150 ml each individual peptide or
pool. Positive control wells received PHA (Thermo Fisher Scien-
tific, Waltham, MA) at 1 mg/ml or CEFT peptide pool (CTL,
Shaker Heights, OH) at 10 mg/ml. Negative control wells only
received culture medium with 0.2% DMSO. At days 3 and 6,
cells were supplemented with 10 ng/ml of IL-2 (BD PharMin-
gen, San Diego, CA) by half media replacement. At day 8,
PBMC were collected and washed in preparation for antigen re-
stimulation to measure cytokine secretion by ELISpot assay. For
HLA-DR blocking experiments, PBMC from the same donor
were cultured in the presence or absence of 5 mg/ml purified
NA/LE mouse anti-human HLA-DR antibody (BD PharMin-
gen, San Diego, CA).
ELISpot Assay
Human IFNg ELISpot assays were performed using a Mab-
tech (Cincinnati, OH) IFNg ELISpot Kit according to the man-
ufacturer’s protocol. Briefly, cells from the 8-day expansion
period were transferred at 1£105/well or 1.5£105/well to ELI-
Spot plates that were pre-coated with anti-human IFNg capture
antibody, and re-stimulated with corresponding peptides at
10 mg/ml. Positive control wells were stimulated with PHA at
1 mg/ml or CEFT at 10 mg/ml. Negative controls only received
culture medium with DMSO at the same concentration as would
be present in peptide-stimulated cultures (0.2%). All stimula-
tions and controls were administered in triplicate wells. ELISpot
plates were incubated for 24 hours at 37C under a 5% CO2
atmosphere, washed and incubated with a secondary HRP-
labeled anti-IFNg detection antibody, and developed by the
addition of TMB substrate. Raw spot counts were recorded using
an ImmunoSpot reader (CTL S5 UV Analyzer). Responses were
considered positive if the number of spots was greater than 50
over background per million PBMC and at least twice the back-
ground. The ELISpot SI was determined by dividing the average
number of spots in each peptide triplicate by the average number
of spots in the negative control wells.
Multicolor flow cytometry
2 £ 106 PBMC were stimulated with individual or pooled
peptides at 10 mg/ml, or culture medium with 0.2% DMSO
(negative control), in the presence of anti-CD49d and anti-CD28
antibody at 0.5 mg/ml (BD PharMingen) over 8 days. IL-2
(10 ng/ml) was added at days 3 and 6. At day 8, PBMC were re-
stimulated with the corresponding peptides at 10 mg/ml or
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negative control for 24 hours. At day 9, cells were collected and
washed in preparation for flow cytometric analysis.
Re-stimulated PBMC were first incubated with fixable viabil-
ity stain 450 (BD Horizon) for 15 minutes at room temperature.
Afterwards, cells were stained with fluorochrome-conjugated
anti-human monoclonal antibodies against T cell surface antigens
(Alexa Fluor 700 anti-CD3, PerCP-Cy5.5 anti-CD4, APC anti-
CD25, and FITC anti-CD39, BD PharMingen) for 30 minutes
at 4C. Cells were then fixed and permeabilized by using FoxP3
Fixation/Permeabilization solution (FoxP3/Transcription Factor
Staining Buffer Set, eBioscience, San Diego, CA) for 30 minutes
at room temperature before being stained with PE-conjugated
anti-human FoxP3 antibody (clone 259D/C7, BD PharMingen)
for at least 30 minutes at room temperature. Cells were washed
with FoxP3 Permeabilization Buffer (eBioscience, San Diego,
CA) and acquired by flow cytometry using a Beckton-Dickinson
LSR-II flow cytometer. Data were analyzed in FlowJo software
(Treestar, Ashland, OR).
Statistical analysis
Tests to determine p-value and statistical significance were
performed using Graphpad Prism or Microsoft Excel. When cor-
relating JanusMatrix Delta with SI, the Pearson function was
used to determine the R value and a regression model of variance
to retrospectively determine study power. Student’s t-test was
used to calculate statistical significance between paired or
unpaired T cell reactivity values.
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